References of "Delanaye, Pierre"
     in
Bookmark and Share    
See detailPlace de la vitamine D native dans le traitement des patients dialysés
DELANAYE, Pierre ULg

Conference given outside the academic context (2015)

Detailed reference viewed: 6 (2 ULg)
See detailPourquoi et comment corriger les anomalies de la PTH ?
DELANAYE, Pierre ULg

Conference given outside the academic context (2015)

Detailed reference viewed: 3 (0 ULg)
Full Text
See detailRituximab (MabThera®) : nouveau médicament dans les vascularites associées à ANCA
VON FRENCKELL, Christian ULg; DELANAYE, Pierre ULg

in Revue Médicale de Liège (2015), 70(2), 92-100

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailExploration de la fonction glomérulaire rénale : estimation du débit de filtration glomérulaire
Maillard, N; DELANAYE, Pierre ULg; Mariat, C

in Néphrologie & Thérapeutique (2015), 11(1), 54-67

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailAn Age-Calibrated Classification of Chronic Kidney Disease.
Glassock, RJ; DELANAYE, Pierre ULg; El-Nahas, M

in JAMA : Journal of the American Medical Association (2015), 314(6), 559-560

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailSafety of living kidney donation: another brick in the wall…and a solid (physiologic) one.
DELANAYE, Pierre ULg; Mariat, C; Glassock, RJ

in American Journal of Kidney Diseases (2015), 66(1), 1-3

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailThe myth of the future burden of CKD in United States.
DELANAYE, Pierre ULg; El-Nahas, M; Glassock, RJ

in American Journal of Kidney Diseases (2015), 66(1), 171-172

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailLifetime Risk of CKD: What Does It Really Mean?
DELANAYE, Pierre ULg; Glassock, RJ

in Clinical Journal of the American Society of Nephrology (2015), 10(9), 1504-1506

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailGlomerular Filtration Rate and Aging: Another Longitudinal Study--A Long Time Coming!
DELANAYE, Pierre ULg; Glassock, rj

in Nephron (2015), 131(1), 1-4

Detailed reference viewed: 2 (0 ULg)
Full Text
Peer Reviewed
See detailAbnormal glomerular filtration rate in children, adolescents and young adults starts below 75 mL/min/1.73 m2
Pottel, Hans; Hoste, Liesbeth; DELANAYE, Pierre ULg

in Pediatric Nephrology : Journal of the International Pediatric Nephrology Association (2015), 30(5), 821-828

Detailed reference viewed: 17 (1 ULg)
Full Text
Peer Reviewed
See detailKDIGO Guidelines and Kidney Transplantation: Is the cystatin-C Based Recommendation relevant?
Masson, I; Maillard, N; CAVALIER, Etienne ULg et al

in American Journal of Transplantation (2015), 15(8), 2211-4

The KDIGO guidelines propose a new approach to diagnose chronic kidney disease (CKD) based on estimated glomerular ®ltration rate (GFR). In patients with a GFR value comprised between 45 and 59 mL/ min/1 ... [more ▼]

The KDIGO guidelines propose a new approach to diagnose chronic kidney disease (CKD) based on estimated glomerular ®ltration rate (GFR). In patients with a GFR value comprised between 45 and 59 mL/ min/1.73m2 as estimated by the CKD-EPI creatinine equation (eGFRcreat), it is suggested to con®rm the diagnosis with a second estimation using the CKD-EPI cystatin C-based equations (eGFRcys/eGFRcreat-cys). We sought to determine whether this new diagnostic strategy might extend to kidney transplant recipients (KTR) and help to identify those with decreased GFR. In 670 KTR for whom a measured GFR was available, we simulated the detection of CKD using the two-steps approach recommended by the guidelines in comparison to the conventional approach relying on creatinine equation. One hundred forty-®ve patients with no albuminuria had eGFRcreat between 45 and 59 mL/ min/1.73m2. Among them, 23% had inulin clearance over 60 mL/min/1.73m2 and were thus incorrectly classi®ed as CKD patients. When applying the Kidney Disease: Improving Global Outcomes (KDIGO) strategy, 138 patients were con®rmed as having a GFR below 60 mL/min with eGFRcreat-cys. However, 21% of them were misclassi®ed in reference to measured GFR. Our data do no not support the use of cystatin C as a con®rmatory test of stage 3A CKD in KTR. [less ▲]

Detailed reference viewed: 23 (4 ULg)
Full Text
Peer Reviewed
See detailSystematic Analysis of two cystatin C assays using samples of 2057 older adults - The Berlin initiative study
Ebert, natalie; DELANAYE, Pierre ULg; Martus, Peter et al

Poster (2014, November)

Detailed reference viewed: 21 (3 ULg)
Full Text
Peer Reviewed
See detailImpact of the dialysis membrane on the Vitamin D metabolims markers
CAVALIER, Etienne ULg; DUBOIS, Bernard ULg; Urena, Pablo et al

Poster (2014, November)

Detailed reference viewed: 16 (3 ULg)
Full Text
Peer Reviewed
See detailCalibration and precision of serum creatinine and plasma cystatin C measurement: impact on the estimation of glomerular filtration rate
DELANAYE, Pierre ULg; CAVALIER, Etienne ULg; Cristol, Jean-Paul et al

in Journal of Nephrology (2014), 27(5), 467-75

Serum creatinine (SCr) is the main variable for estimating glomerular filtration rate (GFR). Due to interassay differences, the prevalence of chronic kidney disease (CKD) varies according to the assay ... [more ▼]

Serum creatinine (SCr) is the main variable for estimating glomerular filtration rate (GFR). Due to interassay differences, the prevalence of chronic kidney disease (CKD) varies according to the assay used, and calibration standardization is necessary. For SCr, isotope dilution mass spectrometry (IDMS) is the gold standard. Systematic differences are observed between Jaffe and enzymatic methods. Manufacturers subtract 0.30 mg/dl from Jaffe results to match enzymatic results (‘compensated Jaffe method’). The analytical performance of enzymatic methods is superior to that of Jaffe methods. In the original Modification of Diet in Renal Disease (MDRD) equation, SCr was measured by a Jaffe Beckman assay, which was later recalibrated. A limitation of this equation was an underestimation of GFR in the high range. The Chronic Kidney Disease Epidemiology (CKD-EPI) consortium proposed an equation using calibrated and IDMS traceable SCr. The gain in performance was due to improving the bias whereas the precision was comparable. The CKD-EPI equation performs better at high GFR levels (GFR[60 ml/ min/1.73 m2). Analytical limitations have led to the recommendation to give a grade ([60 ml/min/1.73 m2) rather than an absolute value with the MDRD equation. By using both enzymatic and calibrated methods, this cutoff-grade could be increased to 90 ml/min/1.73 m2 (with MDRD) and 120 ml/min/1.73 m2 (with CKD-EPI). The superiority of the CKD-EPI equation over MDRD is analytical, but the precision gain is limited. IDMS traceable enzymatic methods have been used in the development of the Lund– Malmo¨ (in CKD populations) and Berlin Initiative Study equations (in the elderly). The analytical errors for cystatin C are grossly comparable to issues found with SCr. Standardization is available since 2011. A reference method for cystatin C is still lacking. Equations based on standardized cystatin C or cystatin C and creatinine have been proposed. The better performance of these equations (especially the combined CKD-EPI equation) has been demonstrated. [less ▲]

Detailed reference viewed: 29 (5 ULg)
Full Text
Peer Reviewed
See detailDephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients.
DELANAYE, Pierre ULg; KRZESINSKI, Jean-Marie ULg; Warling, X et al

in BMC Nephrology (2014), 15

Background: Matrix Gla protein (MGP) is known to act as a potent local inhibitor of vascular calcifications. However, in order to be active, MGP must be phosphorylated and carboxylated, with this last ... [more ▼]

Background: Matrix Gla protein (MGP) is known to act as a potent local inhibitor of vascular calcifications. However, in order to be active, MGP must be phosphorylated and carboxylated, with this last process being dependent on vitamin K. The present study focused on the inactive form of MGP (dephosphorylated and uncarboxylated: dp-ucMGP) in a population of hemodialyzed (HD) patients. Results found in subjects being treated or not with vitamin K antagonist (VKA) were compared and the relationship between dp-ucMGP levels and the vascular calcification score were assessed. Methods: One hundred sixty prevalent HD patients were enrolled into this observational cohort study, including 23 who were receiving VKA treatment. The calcification score was determined (using the Kauppila method) and dp-ucMGP levels were measured using the automated iSYS method. Results: dp-ucMGP levels were much higher in patients being treated with VKA and little overlap was found with those not being treated (5604 [3758; 7836] vs. 1939 [1419; 2841] pmol/L, p <0.0001). In multivariate analysis, treatment with VKA was the most important variable explaining variation in dp-ucMGP levels even when adjusting for all other significant variables. In the 137 untreated patients, dp-ucMGP levels were significantly (p < 0.05) associated both in the uni- and multivariate analysis with age, body mass index, plasma levels of albumin, C-reactive protein, and FGF-23, and the vascular calcification score. Conclusion: We confirmed that the concentration of dp-ucMGP was higher in HD patients being treated with VKA. We observed a significant correlation between dp-ucMGP concentration and the calcification score. Our data support the theoretical role of MGP in the development of vascular calcifications. We confirmed the potential role of the inactive form of MGP in assessing the vitamin K status of the HD patients. [less ▲]

Detailed reference viewed: 18 (0 ULg)
Full Text
Peer Reviewed
See detailInter-method variability in bone alkaline phosphatase measurement : clinical impact on the management of dialysis patients
CAVALIER, Etienne ULg; Souberbielle, Jean-Claude; GADISSEUR, Romy ULg et al

in Clinical Biochemistry (2014), 47(13-14), 1227-30

BACKGROUND: Bone-specific alkaline phosphatase (BAP) is now recommended to assess bone turnover in hemodialysis (HD) patients. However, little is known about potential variability between methods ... [more ▼]

BACKGROUND: Bone-specific alkaline phosphatase (BAP) is now recommended to assess bone turnover in hemodialysis (HD) patients. However, little is known about potential variability between methods available to measure BAP. METHODS: We measured BAP in 76 HD patients with six different assays (Beckman-Coulter Ostase IRMA, Beckman-Coulter Ostase Access, IDS iSYS Ostase, IDS Ostase enzyme immunoassay, DiaSorin Liaison Ostase and Quidel MicroVue BAP). RESULTS: We observed a high correlation between all the assays ranging from 0.9948 (IDS iSYS vs. IDS EIA) to 0.9215 (DiaSorin Liaison vs. Quidel MicroVue). However, using the regression equations, the equivalent concentration of a Beckman-Coulter Access value of 10μg/L can range from 7.7 to 14.4μg/L and of 20μg/L can range from 16.9 to 27.9μg/L with other assays. According to Beckman-Coulter Access, 13%, 50% and 37% of the patients presented BAP values ≤10, between 10 and 20 and ≥20μg/L, respectively. Discrepancies are observed when other assays are used (concordance from 10 to 100%). CONCLUSIONS: Analytical problems leading to inter-method variation should be overcome to improve the usefulness of this marker in clinical practice. According to correlation results, recalibration of BAP assays is necessary but should not be a major issue. [less ▲]

Detailed reference viewed: 47 (19 ULg)
Full Text
Peer Reviewed
See detailStandardization of DiaSorin and Roche automated third generation PTH assays with an international standard: impact on clinical populations
CAVALIER, Etienne ULg; DELANAYE, Pierre ULg; LUKAS, Pierre ULg et al

in Clinical Chemistry & Laboratory Medicine (2014), 52(8), 1137-41

Background: Standardization of parathyroid hormone (PTH) assays is a major issue, especially in hemodialyzed (HD) patients. Two automated third generation PTH assays (Roche Elecsys and DiaSorin Liaison ... [more ▼]

Background: Standardization of parathyroid hormone (PTH) assays is a major issue, especially in hemodialyzed (HD) patients. Two automated third generation PTH assays (Roche Elecsys and DiaSorin Liaison) are now available. These assays are specific for the (1-84) PTH and do not cross-react with the (7-84) fragment, contrary to second generation (intact) assays. We aimed to calibrate the two methods against the WHO International PTH Standard (IS) 95/646 to see if the two assays could provide comparable results in a population of healthy subjects, HD patients and patients suffering from primary hyperparathyroidism (PHP). Methods: We selected 79 healthy subjects and two populations of patients presenting PTH disorders: 56 HD and 27 PHP patients. We reconstituted the IS in a pool of human serum containing undetectable levels of 1-84 PTH and prepared 13 serum standards ranging from 0 to 2000 pg/mL. The standards were run on the two instruments to calibrate the assays on the IS. The different populations were run before and after restandardization. Results: As these kits were differently calibrated, the results obtained after restandarization were significantly different. Restandardization process improved concordance between assays and, taking the analytical variability of the two kits into account, the results could be considered to be similar. Conclusions: Restandardization of automated third generation PTH assays with the WHO 1-84 PTH Standard significantly reduces inter-method variability. Reference ranges and raw values are totally transposable from one method to the other in healthy subjects, but also in diseased patients, e.g., with HD or those suffering from PHP. [less ▲]

Detailed reference viewed: 53 (21 ULg)